



August 30, 2023

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**“Strides receives USFDA approval for Mycophenolate Mofetil for Oral Suspension”**

Thanks & Regards,  
For **Strides Pharma Science Limited**,

**Manjula Ramamurthy**  
**Company Secretary**  
**ICSI Membership No. A30515**

Encl. As above

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

# Strides receives USFDA approval for Mycophenolate Mofetil for Oral Suspension

- *Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, is the first product approval from the Company's flagship facility in Bengaluru, which achieved USFDA inspection closure in February 2023*
- *The approval solidifies the Company's position as the market leader for the Mycophenolate Mofetil products.*
- *Product to be introduced into the market immediately*

**Bangalore, India, Aug 30, 2023** - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, from the United States Food & Drug Administration (USFDA).

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), CellCept for Oral Suspension, 200 mg/mL of Roche Palo Alto, LLC. (Roche). The approval bolsters the Company's Mycophenolate Mofetil portfolio, which already includes numerous products in which the Company is a market leader.

The Mycophenolate Mofetil for Oral Suspension has a market size of ~US\$41 Mn per IQVIA. The entire Mycophenolate Mofetil range of products for the company has a cumulative market opportunity of ~US\$145 Mn per IQVIA. The products will be manufactured at the company's facility in Bengaluru.

The company has 280 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 260+ ANDAs have been approved. The company has set a target to launch ~ 60 new products over three years in the US.

## About Mycophenolate Mofetil for Oral Suspension

Mycophenolate Mofetil for Oral Suspension belongs to a group of medicines called immunosuppressants. After a transplant, it is used with other medicines to prevent the body from rejecting an organ (such as a kidney, heart, or liver). It works by suppressing the body's immune system so that it does not attack the new organ.

## About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at [www.strides.com](http://www.strides.com).

**For further information, please contact:**

**Strides**

**Badree Komandur**

Executive Director – Finance & Group CFO  
+91 80 6784 0747

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi,  
Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,  
Bengaluru – 560076

**Corporate Communication**

**Pallavi Panchmatia:** +91 80 6784 0193

Email: [pallavi.panchmatia@strides.com](mailto:pallavi.panchmatia@strides.com)

**PR Consultancy**

Fortuna PR

K Srinivas Reddy: +91 90005 27213

[srinivas@fortunapr.com](mailto:srinivas@fortunapr.com)

Boni Mukherjee: +91 96186 82208

[boni@fortunapr.com](mailto:boni@fortunapr.com)